Search
Indapamide
go.drugbank.com/drugs/DB00808ApprovedInvestigationalThe most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. … agents may be required in order to achieve blood pressure targets.
Mixtures: CARDIK - IN® 160/2.5, CARDIK - IN® 160/2.5Glutamic acid
go.drugbank.com/drugs/DB00142ApprovedInvestigationalNutraceuticalA peptide that is a homopolymer of glutamic acid.
Mixtures: Aminosyn II in Dextrose, Aminosyn II in DextroseCitric acid
go.drugbank.com/drugs/DB04272ApprovedInvestigationalNutraceuticalVet approvedA key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium-chelating ability. … [L14120] It is also used in combination with magnesium oxide to form magnesium citrate, an osmotic laxative.[L43832]
Mixtures: All-Natural Pen Spray, Pall Sterile Cord Blood Collection UnitCategories: Compounds used in a research, industrial, or household setting, Disinfectants (For Agents Used on Object)Colestipol
go.drugbank.com/drugs/DB00375Approved[FDA Label, F4555, F4567, L6262] In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces … Bile acid sequestrants like colestipol have been in use since the 1970s.
Categories: Compounds used in a research, industrial, or household settingLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success.
Vemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalAfter approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.
Sonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigationallines of systemic therapy, including a BTK inhibitor. … Sonrotoclax is a selective, potent, small-molecule inhibitor of BCL-2, an antiapoptotic protein overexpressed in B-cell malignancies.
Synonyms: N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3- nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin- 1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5- ylAdemetionine
go.drugbank.com/drugs/DB00118ApprovedInvestigationalNutraceuticalPhysiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. … It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Mixtures: HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETLİ ŞİŞE, HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETSİZ ŞİŞESofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalBoth Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [L852, A19626]. … In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Sofosbuvir as first line therapy
Mixtures: MYHEP ALLProducts: I-HEP SOBOVIRCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalAlthough endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative